PPARGC1A and metabolic dysfunction-associated steatotic liver disease: This polymorphism may reduce PGC-1α activities and/or may change its interaction with other transcription factors required to regulate oxidative stress and lipid metabolism, which finally triggers the pathogenesis of NAFLD in type 2 diabetic subjects.